A One-of-a-Kind System.

Models. Not patients.
Does not depict actual treatment.

Optimized for patients, and you.

Our unique selection of applicators helps providers to treat more body areas than any other noninvasive fat-reduction device.* This means providers can create truly customized treatment plans according to individual patient body contouring goals.

*CoolSculpting® has more FDA-cleared treatment areas than any other nonsurgical fat-reduction technology.

Model. Not a patient.

Customized treatments.

Our unique system features responsive and controlled cooling during treatment, with multiple sensors that continuously track the patient's body temperature. The CoolSculpting® system adjusts in real time to maintain the ideal temperature for consistent results.

Patients often want to start with the midsection.

8 out of 10 women who would consider CoolSculpting are concerned about excess fat in the abdomen.1

Together you can develop a plan for other problem areas.

FDA-cleared to treat 9 different areas.

Our range of applicators lets you customize treatments for a variety of stubborn fat areas.

CoolMini®

Applicator ideal for treating smaller areas, such as the submental and submandibular areas, and to improve the appearance of skin laxity in the submental area.

CoolSmooth PRO

Applicator ideal for nonpinchable fat such as the outer thigh.

CoolAdvantage

Applicator ideal for the abdomen, flank, and inner thigh.

CoolAdvantage Plus

Applicator ideal for debulking larger areas.

CoolAdvantage Petite

Applicator ideal for the upper arm and smaller bulges of fat.

Incredible convenience.

Our latest family of applicators offers shorter treatment times, as little as 35 minutes per cycle, depending on the treatment area.

INDICATIONS & SAFETY INFO

CoolSculpting® Indications
The CoolSculpting® procedure is FDA-cleared for the treatment of visible fat bulges in the thigh, abdomen and flank, along with bra fat, back fat, underneath the buttocks (also known as banana roll), and upper arm in patients with a Body Mass Index (BMI) of ≤ 30 and in submental and submandibular areas in patients with a BMI of ≤ 46.2. It is also FDA-cleared to affect the appearance of lax tissue with submental area treatments.

CoolSculpting® Important Safety Information
CoolSculpting® is contraindicated in patients with cryoglobulinemia, cold agglutinin disease, or paroxysmal cold hemoglobinuria.

Ask your patient about any medical conditions including recent surgery, pre-existing hernia, and any known sensitivities or allergies.

During the procedure patients may experience sensations of pulling, tugging, mild pinching, intense cold, tingling, stinging, aching, and cramping at the treatment site. These sensations subside as the area becomes numb. Following the procedure, typical side effects include temporary redness, swelling, blanching, bruising, firmness, tingling, stinging, tenderness, cramping, aching, itching, or skin sensitivity, and sensation of fullness in the back of the throat after submental or submandibular area treatment.

Rare side effects may also occur. Paradoxical hyperplasia (visibly enlarged tissue volume in the treated area) may develop 2-5 months after treatment and requires surgical intervention for correction.

As with any medical procedure, a consultation should be done by a licensed healthcare professional to determine if the patient is a candidate for treatment. Consult the CoolSculpting® System User Manual for a complete list of Contraindications, Warnings, Precautions, and potential side effects. Treatment applications that deviate from the guidelines are not recommended.

 

References: 1. Data on file, Allergan, 2016; CoolSculpting Consumer Awareness, Market Sizing, and Attitudinal Insights Study.

INDICATIONS & SAFETY INFO
CoolSculpting® Indications
CoolSculpting® procedure is FDA-cleared for the treatment of visible fat bulges in the thigh, abdomen and flank, along with bra fat, back fat, underneath the buttocks (also known as banana roll), and upper arm in patients with a Body Mass Index (BMI) of ≤ 30 and in submental and submandibular areas in patients with a BMI of ≤ 46.2. It is also FDA-cleared to affect the appearance of lax tissue with submental area treatments.
INDICATIONS & SAFETY INFO